Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

Infertility Specialist Richard Sherbahn Presents New Research Study at the American Society for Reproductive Medicine Annual Meeting
  • USA - English


News provided by

Advanced Fertility Center of Chicago

Jan 15, 2015, 03:00 ET

Share this article

Share toX

Share this article

Share toX


IVF success rates can be excellent for high responding women when using a Lupron trigger.

Post this

Gurnee, IL (PRWEB) January 15, 2015 -- Board-certified fertility specialist Richard Sherbahn, MD recently presented research on the use of a Lupron trigger (agonist trigger) to prevent ovarian hyperstimulation in women with a high response to ovarian stimulation for IVF at the annual meeting of the American Society for Reproductive Medicine in Honolulu, Hawaii. The study, conducted by Dr. Sherbahn and Dr. Catenacci of Advanced Fertility Center of Chicago, looked at IVF live birth success rates, pregnancy loss rates, and ovarian hyperstimulation syndrome (OHSS) occurrence rates in high responders that had a pure Lupron trigger vs. a dual trigger with Lupron and a small dose of HCG.

Included in the study were 135 women under the age of 38, all using their own eggs for in-vitro fertilization (IVF). They each either received a pure Lupron trigger or a Lupron trigger plus a small dose of HCG (1500-2000 units), between November 2011 and July 2013. Patients were separated into 2 groups based on their trigger injections (pure agonist trigger vs dual trigger). Intensive support was given in the luteal phase using intramuscular progesterone and oral or transdermal estradiol.

The mean number of eggs retrieved, miscarriage rates, and the rate of development of ovarian hyperstimulation syndrome were not significantly different between the pure Lupron trigger group and the dual trigger group. The live birth rate per egg retrieval was 52.6% in the pure agonist trigger group, while the dual trigger group rate was 64.4%. The difference was not statistically significant. There was a trend for higher pregnancy loss rates in the pure agonist group, but it was not statistically significant either.

The pure Lupron trigger group was then split into 2 groups according to the peak estradiol level - under or over 4000 pg/ml. The IVF live birth rate was significantly higher (p<0.05) in the group with peak estradiol levels greater than 4000 pg/ml (42.2% vs. 67.7%).

“Published studies on Lupron triggers, and other agonist drug triggers, have shown inconsistent results. We believe that, in the studies with poor IVF success rates, the patients were not given enough estrogen and progesterone support in the luteal phase and early pregnancy. We believe the luteal support needs to be aggressive, and must be continued into early pregnancy, until the placenta makes enough hormones to support the pregnancy,” explained Dr. Sherbahn.

The results of the study showed that live birth rates with IVF, using a pure agonist trigger, can be very high when intensive luteal support is given. Also, success rates using a pure Lupron trigger are significantly higher when the peak estradiol level is above 4000 pg/ml. Therefore, if the peak estradiol level is below 4000 pg/ml, a dual trigger with a low dose of 1500 IU of HCG should be considered.

“We believe that the Lupron trigger is a vital tool that has been available to IVF doctors for the last several years for reducing the occurrence of ovarian hyperstimulation – particularly in women with polycystic ovarian syndrome, PCOS. Before the Lupron trigger was available, there were significantly more cases of ovarian hyperstimulation syndrome, which is always uncomfortable for the woman, and in rare cases can result in severe medical complications,” said Sherbahn. Proper use of pure agonist triggers can result in excellent IVF success rates, and no ovarian hyperstimulation, or rare hyperstimulation cases with a dual trigger.

About The Advanced Fertility Center of Chicago

The Advanced Fertility Center of Chicago, with offices in Gurnee and Crystal Lake, Ill., offers advanced reproductive technology services such as in-vitro fertilization (IVF), intracytoplasmic sperm injection, preimplantation genetic diagnosis, egg freezing and egg donation.

The Center specializes in individualized care, and has IVF success rates and egg donation success rates that are well above national averages.

The Center’s web site, http://www.advancedfertility.com, offers more than 300 articles on fertility issues and IVF. To schedule an appointment, call 847.662.1818.

Richard Sherbahn, Advanced Fertility Center of Chicago, http://www.advancedfertility.com, +1 (847) 662-1818, [email protected]

Modal title

Live Birth and OHSS Rates with Lupron Trigger vs. Dual Trigger
Live Birth and OHSS Rates with Lupron Trigger vs. Dual Trigger
Live Birth and OHSS Rates with Lupron Trigger vs. Dual Trigger

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.